# ClearNote Health

Source: https://onco.cc/companies/clearnote-health/  
OnCo record `clearnote-health` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ClearNote Health sells blood tests that look for chemical marks on DNA fragments in the blood to catch pancreatic and ovarian cancer early in people at high risk.

## Summary

ClearNote Health (formerly Bluestar Genomics) is a San Diego epigenomics company whose Avantect tests analyse cell-free DNA in plasma with a proprietary platform that captures epigenomic changes, combined with machine learning, to detect cancer signal in high-risk groups. The Avantect Pancreatic Cancer Test targets people with new-onset diabetes and other risk factors; an Avantect Ovarian Cancer Test and a multi-cancer detection programme are in development. The pancreatic test runs from a CLIA-certified, CAP-accredited laboratory, received a first in vitro diagnostic approval in July 2025 and a UK approval in September 2025, and validation data were shown at AACR, DDW and ASCO in 2026. In May 2026 the company closed a $52 million Series D led by founding investor Mattias Westman, with Sandy Weill and Stephen Quake participating, for over $185 million raised in total.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: San Diego, CA
- Type: diagnostics
- Website: https://www.clearnotehealth.com/

## Notes

- Multi-cancer test (29 October 2026): the Avantect Multi-Cancer Detection Test, UKCA-marked in September 2025 by the company's account, is one of the two tests in the NCI Vanguard Study. The platform reads 5-hydroxymethylcytosine in cell-free DNA, as its peer-reviewed papers state (Chowdhury et al., J Mol Diagn 2024; Xue et al., Commun Biol 2025). Earlier rounds (Series B, C) not sourced. Founding year not sourced.

## Sources

- Official website: https://www.clearnotehealth.com/
- Series D press release (May 2026): https://www.clearnotehealth.com/clearnote-health-secures-52-million-in-series-d-financing-and-strengthens-leadership-team-to-accelerate-growth-in-early-cancer-detection/
- Press release archive: https://www.clearnotehealth.com/category/press-release/

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [DNA methylation profiling](https://onco.cc/technologies/methylation-profiling/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Avantect Multi-Cancer Detection Test](https://onco.cc/drugs/avantect-mcd/)
- trials: [ClearNote Health multi-cancer epigenomics study](https://onco.cc/trials/clearnote-multi-cancer-epigenomics/), [Inova burn pit veterans cancer screening pilot](https://onco.cc/trials/inova-burn-pit-screening/), [Vanguard Study (NCI Cancer Screening Research Network)](https://onco.cc/trials/vanguard-study/)

---
JSON: https://onco.cc/api/v1/entities/clearnote-health.json